Lipoprotein(a) testing and levels among patients with atherosclerotic cardiovascular disease: a large single-centre experience from the United Arab Emirates - Takeaways - MDSpire

Lipoprotein(a) testing and levels among patients with atherosclerotic cardiovascular disease: a large single-centre experience from the United Arab Emirates

  • By

  • Yosef Manla

  • Laila AbdelWareth

  • Yazan Aljabery

  • Hani Sabbour

  • Ronney Shantouf

  • Fatemeh Mohammad

  • Bartlomiej Piechowski-Jozwiak

  • Terrence Lee St John

  • Wael Almahmeed

  • June 26, 2025

  • 0 min

Share

  • 1

    Only 5.5% of patients with atherosclerotic cardiovascular disease (ASCVD) underwent lipoprotein(a) testing, despite guideline recommendations.

  • 2

    Patients with premature ASCVD had higher Lp(a) testing rates (7%) and elevated median Lp(a) levels compared to those with non-premature ASCVD.

  • 3

    Testing for Lp(a) increased by 55.8% overall and 75.5% in the premature ASCVD subgroup between 2018 and 2022.

  • 4

    Patients tested for Lp(a) were younger, more often male, and had a higher prevalence of hyperlipidaemia and coronary artery disease.

  • 5

    Higher Lp(a) levels were associated with increased likelihood of treatment with ezetimibe and PCSK9 inhibitors within three months post-testing.

Original Source(s)

Lipoprotein(a) testing and levels among patients with atherosclerotic cardiovascular disease: a large single-centre experience from the United Arab Emirates

  • by Yosef Manla, Laila AbdelWareth, Yazan Aljabery, Hani Sabbour, Ronney Shantouf, Fatemeh Mohammad, Bartlomiej Piechowski-Jozwiak, Terrence Lee St John, Wael Almahmeed

  • June 26, 2025

Related Content

Advancing Stroke Care: WashU Medicine Specialists at Barnes-Jewish Hospital Help Chronic Stroke Patients with Innovative Use of Vagus Nerve Stimulation

For years, chronic stroke patients heard familiar feedback regarding their ability to regain strength and mobility after ischemic strokes caused upper-extremity deficits.

  • by

  • May 6, 2026

  • 7 min
Occludin-mediated barrier dysfunction and its role in cardiovascular and cerebrovascular pathogenesis

Prevalence and risk factors of cognitive impairment in patients with coronary heart disease: a systematic review and meta-analysis